172 results
8-K
EX-99.1
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
represents a transformational milestone for Akebia as we initiate launch activities that we believe will enable widespread access and rapid adoption … discussions with dialysis organizations with a goal to ensure broad access to Auryxia.
“With continued revenue contributions from Auryxia, revenue
DEFA14A
AKBA
Akebia Therapeutics Inc.
25 Apr 24
Additional proxy soliciting materials
5:18pm
.
THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. We encourage you to access
8-K
AKBA
Akebia Therapeutics Inc.
23 Apr 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
8:32am
(the “Term Loan Facility”). The Loan Agreement provided the Company access to an initial tranche of $37.0 million, which was funded on the Closing Date
8-K
EX-99.1
r9fvvco vk
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
8-K
EX-99.1
f309 c0bl3mn67wru
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
9w3bii2 t7qve3di7p
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
EX-99.1
o71lxmv q81bm8
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
ozyvn 2kac9
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
8-K
EX-99.1
e7k061 4obc1
7 Jun 23
Regulation FD Disclosure
7:31am
8-K
2bqnkhm4
30 May 23
Regulation FD Disclosure
7:34am